Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Pharma Mar, S.A.    PHM   ES0169501022

PHARMA MAR, S.A.

(PHM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
91.55(c) 95.05(c) 95.95(c) 96.7(c) 97.45(c) Last
223 260 197 165 183 215 228 003 123 459 Volume
+2.92% +3.82% +0.95% +0.78% +0.78% Change
More quotes
Financials
Sales 2020 320 M 386 M 386 M
Net income 2020 178 M 214 M 214 M
Net cash position 2020 203 M 245 M 245 M
P/E ratio 2020 10,1x
Yield 2020 0,37%
Sales 2021 246 M 297 M 297 M
Net income 2021 88,5 M 107 M 107 M
Net cash position 2021 164 M 197 M 197 M
P/E ratio 2021 20,4x
Yield 2021 0,64%
Capitalization 1 802 M 2 173 M 2 175 M
EV / Sales 2020 5,00x
EV / Sales 2021 6,65x
Nbr of Employees 487
Free-Float 73,8%
More Financials
Company
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent,... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Notations Surperformance© of Pharma Mar, S.A.
Trading Rating : Investor Rating :
More Ratings
All news about PHARMA MAR, S.A.
11/25PHARMA MAR S A : GENOMICA, PharmaMar Group, launches a new PCR test that can det..
AQ
11/24PHARMA MAR S A : On business and financial situation
PU
11/23PHARMA MAR S A : Other relevant information
PU
11/17PHARMA MAR S A : PharmaMar and STADA sign agreement to commercialize Yondelis® (..
PU
11/10PHARMA MAR S A : On business and financial situation
PU
11/04PHARMA MAR S A : PharmaMar Group presents results up to September 30th 2020
AQ
11/03PHARMA MAR S A : PharmaMar Group presents results up to September 30th 2020
PU
10/29PHARMA MAR S A : The General Court of the European Union agrees with PharmaMar o..
AQ
10/28PHARMA MAR S A : On financial instruments
PU
10/28PHARMA MAR S A : The General Court of the European Union agrees with PharmaMar o..
PU
10/19PHARMA MAR S A : PharmaMar announces positive results of its APLICOV trial again..
AQ
10/16PHARMA MAR S A : PharmaMar signs an agreement with Jazz Pharmaceuticals for lurb..
AQ
10/16PHARMA MAR S A : PharmaMar announces positive results of its APLICOV trial again..
PU
10/16PHARMA MAR S A : On business and financial situation
PU
10/15PHARMA MAR S A : Jazz Pharmaceuticals plc - New Data for Zepzelca to be presente..
AQ
More news
News in other languages on PHARMA MAR, S.A.
07/15PHARMA MAR, S.A. : Veröffentlichung des Halbjahresergebnisses
07/15PHARMA MAR, S.A. : publication des résultats semestriels
04/14CORONAVIRUS : le fil des actus positives
03/13Pharma Mar veut tester l'Aplidin contre le COVID-19
More news
Stock Trading Strategies
PHARMA MAR, S.A. - 09/10
Expect the comeback of a strong trend
BUY
More Stock Trading Analysis
Chart PHARMA MAR, S.A.
Duration : Period :
Pharma Mar, S.A. Technical Analysis Chart | PHM | ES0169501022 | MarketScreener
Technical analysis trends PHARMA MAR, S.A.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 126,67 €
Last Close Price 97,45 €
Spread / Highest target 79,6%
Spread / Average Target 30,0%
Spread / Lowest Target -1,49%
EPS Revisions
Managers
NameTitle
José Maria Fernández de Sousa-Faro Executive Chairman, President & CEO
Maria Luisa de Francia Caballero Chief Financial Officer
Nadia Badri Vice President-Medical Affairs
Carmen Cuevas Marchante Director-Research & Development
Ali Zeaiter Director-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
PHARMA MAR, S.A.2,629.69%2 115
CSL LIMITED7.84%99 427
SAMSUNG BIOLOGICS CO.,LTD.81.52%46 940
BIOGEN INC.-19.06%36 958
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.151.53%30 386
ALEXION PHARMACEUTICALS, INC.14.50%26 723